Exact Sciences Corporation (EXAS) Insider Kevin T. Conroy Sells 134,057 Shares

Exact Sciences Corporation (NASDAQ:EXAS) insider Kevin T. Conroy sold 134,057 shares of Exact Sciences Corporation stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total value of $7,976,391.50. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Exact Sciences Corporation (NASDAQ EXAS) traded down $0.57 during midday trading on Wednesday, reaching $59.17. The company’s stock had a trading volume of 745,440 shares, compared to its average volume of 2,511,738. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $63.60.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company’s quarterly revenue was up 158.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.36) EPS. equities research analysts forecast that Exact Sciences Corporation will post -1.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Exact Sciences Corporation (EXAS) Insider Kevin T. Conroy Sells 134,057 Shares” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://stocknewstimes.com/2017/11/22/exact-sciences-corporation-exas-insider-kevin-t-conroy-sells-134057-shares.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio raised its holdings in Exact Sciences Corporation by 69.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 122,201 shares of the medical research company’s stock valued at $5,758,000 after acquiring an additional 50,185 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new position in Exact Sciences Corporation in the 3rd quarter valued at $514,000. California Public Employees Retirement System increased its stake in shares of Exact Sciences Corporation by 2.8% in the 3rd quarter. California Public Employees Retirement System now owns 190,338 shares of the medical research company’s stock valued at $8,969,000 after purchasing an additional 5,238 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Exact Sciences Corporation by 117.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,730 shares of the medical research company’s stock valued at $327,000 after purchasing an additional 3,642 shares during the last quarter. Finally, AlphaStar Capital Management LLC bought a new position in shares of Exact Sciences Corporation in the 3rd quarter valued at $322,000. 86.04% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently commented on EXAS. Vetr upgraded Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 target price for the company in a research note on Tuesday, July 25th. Roth Capital lifted their price target on Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, July 26th. Lake Street Capital lifted their price target on Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a report on Wednesday, July 26th. Robert W. Baird lifted their price target on Exact Sciences Corporation from $49.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. Finally, Jefferies Group LLC lifted their price target on Exact Sciences Corporation to $60.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Exact Sciences Corporation currently has a consensus rating of “Buy” and an average target price of $49.98.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply